SCHEMBL469734

SCHEMBL469734

NC(=S)c1ccc(O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
HTT P42858 3/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
MAPT P10636 4/20 0.47
HPGD P15428 4/20 0.47
ALDH1A1 P00352 4/20 0.47
HSD17B10 Q99714 3/20 0.47
CA3 P07451 3/20 0.47
CA14 Q9ULX7 3/20 0.47
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
TYR P14679 2/20 0.47
CA4 P22748 2/20 0.47
CA5A P35218 2/20 0.47
CA9 Q16790 2/20 0.47
CA5B Q9Y2D0 2/20 0.47
CYP3A4 P08684 2/20 0.47
ALOX15 P16050 2/20 0.47
KMT2A Q03164 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18155125 0.92 ESR1 (0.55) LMNAHTTSMN1; SMN2MAPTKMT2A
SCHEMBL27970358 0.88 MAPK1 (0.56) LMNAHTTSMN1; SMN2MAPTALOX15
SCHEMBL2206586 0.87 HTT (0.62) LMNAHTTSMN1; SMN2MAPTHSD17B10
SCHEMBL27405389 0.82 NPC1 (0.61) SMN1; SMN2ALDH1A1CYP3A4HIF1AKDM4E
Hydroquinone SCHEMBL18203134 0.81 CA2 (0.61) LMNAMAPTHPGDALDH1A1HSD17B10
SCHEMBL14018619 0.77 HTT (0.58) LMNAHTTSMN1; SMN2MAPTALDH1A1
SCHEMBL11673671 0.75 MAPT (0.53) LMNAHTTSMN1; SMN2MAPTHPGD
SCHEMBL10503095 0.74 HTT (0.50) LMNAHTTSMN1; SMN2MAPTHSD17B10
SCHEMBL999667 0.74 HTT (0.50) HTTSMN1; SMN2ALDH1A1CA1CA2
SCHEMBL22130014 0.74 HTT (0.50) HTTSMN1; SMN2ALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 422 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746860-A1 HYDROGEN SULPHIDE FOR TOPICAL TREATMENT OF NAIL INFECTION KING'S COLLEGE LONDON (GB) 2026-05-27 EP claimed
CN-122060333-A High-temperature-resistant silicon rubber and preparation method and application thereof 东莞宏强新材料有限公司 2026-05-19 CN claimed
CN-119019771-B Mining high wear-resisting rubber sleeve cable 天环线缆集团有限公司 2025-03-04 CN claimed
WO-2025017299-A1 HYDROGEN SULPHIDE FOR TOPICAL TREATMENT OF NAIL INFECTION KING'S COLLEGE LONDON (GB) 2025-01-23 WO claimed
CN-119019771-A Mining high wear-resisting rubber sleeve cable 天环线缆集团有限公司 2024-11-26 CN claimed
CN-118845638-A Choline-based melittin composite ionic liquid preparation as well as preparation method and application thereof 重庆医科大学 2024-10-29 CN claimed
CN-118685991-A Antibacterial deodorizing jacket and processing technology thereof 温州东昊服饰有限公司 2024-09-24 CN claimed
EP-4414363-A1 INDOLYLACETIC DERIVATIVES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Miuli Pharma S.r.l. (IT) 2024-08-14 EP claimed
CN-117924211-A Preparation method of febuxostat 哈药集团技术中心 2024-04-26 CN claimed
CN-110790720-B Novel preparation method of febuxostat intermediate 内蒙古京东药业有限公司 2023-06-27 CN claimed
CN-102086169-A Preparation method of intermediates of Febuxostat CHONGQING PHARM RES INST CO 2011-06-08 CN claimed
CN-101412699-A Preparation of 2-(3-carboxaldehyde-4-hydroxy phenyl)-4-methyl-5-thiazole ethyl formate SHANGHAI INST PHARM INDUSTRY (CN) 2009-04-22 CN claimed
JP-2007500724-A 2007-01-18 JP claimed
EP-1651624-A2 PROCESS FOR THE PREPARATION OF SUBSTITUTED THIAZOLES Abbott Laboratories (US) 2006-05-03 EP claimed
US-20050075323-A1 Beta3 adrenergic receptor agonists and uses thereof PFIZER INC 2005-04-07 US claimed
US-20050075503-A1 Substituted thiazoles ABBVIE INC. 2005-04-07 US claimed
WO-2005012273-A2 PROCESS FOR THE PREPARATION OF SUBSTITUTED THIAZOLES ABBOTT LABORATORIES (US) 2005-02-10 WO claimed
US-20050027128-A1 Substituted thiazoles ABBOTT LABORATORIES 2005-02-03 US claimed
US-20030203913-A1 Beta3 adrenergic receptor agonists and uses thereof PFIZER INC. 2003-10-30 US claimed
US-20020052392-A1 Bita3 adrenergic receptor agonists and uses thereof DAY ROBERT F (US) 2002-05-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203913-A1 Beta3 adrenergic receptor agonists and uses thereof ADRB3, ADRB1, ADRB2 LMNA 1468/4885HTT 3936/4885SMN1; SMN2 2178/4885
US-20050027128-A1 Substituted thiazoles XDH, TH, TPI1 LMNA 3986/4885HTT 1192/4885SMN1; SMN2 4667/4885
US-20050075323-A1 Beta3 adrenergic receptor agonists and uses thereof ADRB3, ADRB1, ADRB2 LMNA 1332/4885HTT 3679/4885SMN1; SMN2 2100/4885
US-20050075503-A1 Substituted thiazoles XDH, TH, TPI1 LMNA 3986/4885HTT 1192/4885SMN1; SMN2 4667/4885
US-20020052392-A1 Bita3 adrenergic receptor agonists and uses thereof ADRB3, ADRA1A, ADRB1 LMNA 1800/4885HTT 3700/4885SMN1; SMN2 3271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.